Edition:
United Kingdom

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

30.65USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$30.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
80,596
52-wk High
$37.45
52-wk Low
$22.10

Select another date:

Tue, May 8 2018

BRIEF-Revance Reports Qtrly Loss Per Share $0.97

* REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018 Source text for Eikon: Further company coverage:

Mylan teams up with Revance on biosimilar for Botox

NEW YORK Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment.

CORRECTED-Mylan teams up with Revance on biosimilar for Botox

NEW YORK, Feb 28 Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment.

BRIEF-Revance Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $1.14

* REVANCE THERAPEUTICS INC - ‍REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018​

BRIEF-Revance Therapeutics, Mylan Ireland Enter Collaboration Deal‍

* REVANCE THERAPEUTICS SAYS ‍CO, MYLAN IRELAND LIMITED ENTERED INTO COLLABORATION DEAL- SEC FILING​

BRIEF-Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis

* REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS

BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018

* REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018

Select another date: